Simultaneous inhibition of the phosphoinositide 3-kinase (PI3K) signaling pathway and histone deacetylase (HDAC) provides synergistic efficacy in the treatment of hematological malignancies.
What had been viewed as a major catalyst for Gilead Sciences Inc. going into 2024 turned into a disappointment on the stock market, as antibody-drug conjugate Trodelvy (sacituzumab govitecan) failed to meet the overall survival primary endpoint in the phase III Evoke-01 study in previously treated metastatic non-small-cell lung cancer (NSCLC).
Despite treatment with temozolomide and radiation therapy, patients with glioblastoma usually develop refractory disease, and thus have a poor prognosis (median overall survival of 15 months); here, the DNA damage response (DDR) mechanism shown by cancer cells plays a key role.
Chinese researchers have presented data on a novel six-gene prognostic risk model for breast cancer based on data from the The Cancer Genome Atlas (TCGA) database.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia that accounts for around 25% of ALL cases. In recent years, novel strategies have emerged to reduce the dependence on intensive chemotherapy or hematopoietic stem cell transplantation, but there is still a need for new options with better efficacy in this setting.
The identification of novel immunotherapeutic targets for the treatment of biliary tract cancer (BTC) is still a need. It has been reported that galectin-9 (GAL-9) is expressed in BTC and induces immunosuppressive effects, such as inducing apoptosis in T cells when binding to its receptor TIM-3.
Researchers from St. Jude Children’s Research Hospital have reported the discovery of SJ-3149, a novel selective CK1α degrader being developed for the treatment of cancer.
As gene therapies gain unprecedented traction into 2024, preclinical-stage South Korean biotech Genecraft Inc. said it raised ₩10 billion (US$7.48 million) in a series A financing to further R&D for its therapy against lung cancer.
RSS
